Prolonged glucocorticoid steroid treatment is associated with linear growth failure, excessive weight gain and heightened risk of osteoporosis [12, 13] .
Comparative studies of prednisone and deflazacort in DMD have been based on randomized trials [14] [15] [16] , post-hoc analyses of placebo-arm data [17, 18] and on longer term analyses of natural history data [9] [10] [11] . While clinical trials are the gold standard for assessing the efficacy and safety of therapeutics, data from electronic health records of patients seen in clinics can be used to assess real-world outcomes. We aimed to study the outcomes associated with deflazacort and prednisone/prednisolone treatments, including ambulatory, pulmonary, cardiac, growth and bone-health outcomes, in patients with DMD with the use of real-world data from a large, single center cohort receiving coordinated, collaborative and interdisciplinary patient-and family-centered care consistent with modern guidelines for the management of DMD [19] .
Patients
This is a retrospective cohort analysis of clinical data from electronic health records of patients with DMD who attended the Comprehensive Neuromuscular Center at Cincinnati Children's Hospital Medical Center (CCHMC) from 2004 to March 2017. The de-identified data from an institutional review board (IRB) approved electronic clinic registry (IRB #2010-1881) were curated for the following variables of interest: demographics, vitals, glucocorticoid steroid use, bone density and body composition (via dual-energy x-ray absorptiometry [DEXA] scans), diagnosis of scoliosis and measures of ambulatory, pulmonary and cardiac function. Patients included in the present study were required to have a recorded date of steroid initiation and a recorded steroid type in the CCHMC database. The majority (99%) of clinic visits and follow-up time included in this study occurred prior to the US FDA approval of deflazacort in February 2017; during this period patients took imported deflazacort. The outcomes of interest were ages at clinical events (loss of ambulation and scoliosis); patients' ambulatory, pulmonary and cardiac function; and weight, lean body mass and bone health.
Statistical methods

Analyses of ages at clinical events
For the analyses of ages at clinical events, included patients were categorized into prednisone-and deflazacortinitiated groups based on their first recorded steroid type. Patient characteristics during the first clinic visit and their dosing regimens (daily vs other) were summarized in these groups. Means and standard deviations (SD) were reported for continuous characteristics; counts and percentages were reported for categorical characteristics.
Loss of ambulation was identified as Functional Mobility Scale (FMS) score >4, which is indicative of patients' full-time use of a wheelchair for mobility in DMD. The FMS ranges from 1 (mild gait abnormalities) to 8 (unable to sit without support) with FMS 1-4 for ambulatory patients and 5-8 for nonambulatory patients. Patients studied for this outcome were required to have an FMS score of 1-4 at their first clinic visit.
Age at onset of scoliosis was defined as the first recorded clinical diagnosis of scoliosis in the patient's medical record. Clinical diagnosis of scoliosis at CCHMC is determined based on clinical examination and confirmation with spine radiographic reports finding Cobb's angle >20 degrees. Patients studied for time to scoliosis were required to be free of scoliosis at their first clinic visit.
Age at first occurrence of FMS >4 and first diagnosis of scoliosis were studied in time-to-event analyses, with age as the time variable, and censoring at the end of data availability. Kaplan-Meier curves and log-rank tests were calculated to compare these outcomes between steroid initiation groups. Cox proportional hazards analyses were used to estimate the association between steroid type and age at event while adjusting for age at steroid initiation, the calendar year during which the patient had initiated steroid use, and whether the patient had initiated steroids prior to or after their first clinic visit at CCHMC. The adjusted analyses thus accounted for differences in the duration of steroid exposure, potential temporal trends that might impact outcomes across groups, and potential differences in care received prior to CCHMC. Sensitivity analyses were conducted distinguishing between patients who received daily versus other regimens of prednisone and, separately, distinguishing those who maintained prednisone versus those who switched to deflazacort after initiation.
Analyses of average outcomes across clinic visits
For the analyses of associations between steroid type and clinical status, patients' clinic visits were included in the analysis if the patient was ≥4 years of age at the visit and consistently used either prednisone or deflazacort while under care at CCHMC. Patients who switched steroids were excluded from this analysis, as the precise date of switching was not always available. Studied outcomes included: functional outcomes ( ; and bone health assessed as whole body bone mineral density (BMD in g/cm 2 ) using DEXA. Analyses of each outcome included only those visits at which the outcome was measured. For ambulatory function tests, this excluded visits at which the test was not conducted because the patient was not willing or able to complete the test.
Multivariable regression analyses were used to estimate cross-sectional associations between steroid type (deflazacort or prednisone) and each outcome measure across all assessments. These analyses estimated the average differences observed during clinic visits between patients receiving deflazacort and those receiving prednisone. The analyses were adjusted for current age, years since steroid initiation, whether the patient had begun taking steroids prior to or after their first clinic visit at CCHMC, and current visit year, as well as the interaction between current age and years since steroid initiation. The inclusion of the interaction term allows the effect of duration of steroid exposure to potentially vary by current age. Adjustment for visit year (i.e., the calendar year of the visit) accounts for potential temporal factors that might have influenced outcomes. Adjusting for whether the patient had initiated steroids prior to or after their first clinic visit at CCHMC accounts for potential differences in care received prior to CCHMC. Generalized estimating equations with an exchangeable correlation structure were used to account for the use of multiple clinic visits per patient.
Results
Patient characteristics
Among n = 600 total boys in the CCHMC database, n = 559 had their date of steroid initiation recorded and n = 500 had a steroid type recorded at some point during their follow-up history at CCHMC. A further n = 435 of these patients had at least one assessment of FMS or an assessment for scoliosis. Among these patients, at their first clinic visit at CCHMC, those treated with prednisone (n = 105; 68% daily) had a mean (±SD) age of 8.1 (±3.1) years, while patients treated with deflazacort (n = 330; 95% daily) had a mean age of 6.5 (±3.1) years ( Table 1) . A little over half of the patients had initiated steroids prior to their first clinic visit at CCHMC, and the proportion doing so differed by steroid type (75% for prednisone and 48% for deflazacort); for these patients the average time between steroid initiation and first clinic visit was similar between steroid groups at 2.5 and 2.3 years, respectively. The overall average follow-up included in the time-to-event analyses was 11.2 years in the FMS analyses and 11.9 years in the scoliosis analyses. The follow-up time was similar across prednisone-and deflazacort-initiated patients (<6 months difference in mean follow-up time).
At first clinic visit at CCHMC with functional data recorded, deflazacort-initiated patients were on average younger, shorter and weighed less, compared with prednisone-initiated patients ( Table 1 ). The deflazacortinitiated group was also younger on average at steroid initiation compared with the prednisone-initiated group (5.7 vs 6.4 years, respectively). Across measures of ambulatory, pulmonary and cardiac function at the first clinic visit at CCHMC, deflazacort-treated patients tended to have better or similar function compared with prednisone-treated patients. Figure 1 ). Loss of ambulation occurred at significantly older ages for deflazacort-initiated patients; the median age at transition was 15.6 years in the deflazacort-initiated group and 13.5 years in the prednisone-initiated group (log-rank p < 0.01). By age 15 years, 56% of prednisoneinitiated patients had lost ambulation, compared with 43.7% of deflazacort-initiated patients.
Analyses of ages at clinical events
During follow-up at CCHMC, 42 patients developed scoliosis (deflazacort-initiated patients: 7.9% [25/317]; prednisone-initiated patients: 17.9% [17/95]) ( Figure 2 ). Scoliosis occurred at significantly older ages for patients initiating deflazacort compared with prednisone; the median age was not reached in the deflazacort-initiated group, whereas the median age of scoliosis onset was 18.6 years in the prednisone-initiated group (log-rank test p = 0.05). Based on the Kaplan-Meier estimates, by age 15 years, 13.7% of prednisone-initiated patients and 8.9% of deflazacort-initiated patients had scoliosis.
These associations persisted in Cox proportional hazards analyses that adjusted for age at steroid initiation, year of steroid initiation and whether the patient had initiated steroids prior to or after their first clinic visit at CCHMC future science group www.futuremedicine.com ( Table 3 ). Relative to treatment with prednisone, treatment with deflazacort was associated with a reduction in the hazard of loss of ambulation by 53% and with a reduction in the hazard of scoliosis by 59%. Hazard ratios were similar in both the adjusted and unadjusted analyses. The age at loss of ambulation findings were robust to a sensitivity analysis that excluded the n = 11 patients who required orthotics or braces to walk at their first assessment (i.e., FMS = 4). In sensitivity analyses with dosing frequency data available, comparisons between deflazacort (95% daily) and separated groups receiving daily versus other regimens of prednisone yielded findings consistent with those of the main analyses for ages at loss of ambulation and scoliosis (Supplementary Table 1 ).
In the separate sensitivity analyses among patients with switching data available, there were n = 44 patients initiated on prednisone who switched to deflazacort (42% out of 105) and n = 14 who initiated on deflazacort and switched to prednisone (4.2% out of 330). Among the subset of switchers from prednisone to deflazacort with duration data available (about 28% of the n = 44), the average duration on prednisone was 3.1 years and the average subsequent duration on deflazacort was 2.5 years. Times to scoliosis and loss of ambulation among prednisone-to-deflazacort switchers were numerically prolonged compared with patients continuing on prednisone, but shorter compared with patients initiated with deflazacort (Supplementary Table 2 ). Initiation with deflazacort was associated with a reduction in the hazard of loss of ambulation by 64% relative to being treated with prednisone only. Switching from prednisone to deflazacort was numerically associated with a reduction in the hazard of loss of ambulation by 51% relative to being treated with prednisone only. Similarly, initiation with deflazacort was associated with a reduction in the hazard of incurring the onset of scoliosis by 61%, and switching from prednisone Log-rank p = 0.05 to deflazacort was numerically associated with a reduction in the hazard of incurring scoliosis by 13%, relative to being treated with prednisone only.
Analyses of average outcomes across clinic visits
When analyzing associations between steroid type and outcomes across all clinic visits, the sample sizes varied according to the assessment frequency of each outcome as follows: 4SC velocity: 1519 total observations from 285 patients; 30-ft walk/run velocity: 1794 observations from 303 patients; timed sit-to-stand velocity: 1651 observations from 294 patients; NSAA: 1400 total observations from 294 patients; FVC %-predicted: 1193 total 
Cross-sectional analyses
Cross-sectional associations between steroid type and patient status across all clinic visits (unadjusted and adjusted) are summarized in Table 2 . After adjusting for age at the clinic visit, steroid duration as of the visit, the calendar year of the visit, and whether the patient had initiated steroids prior to or after their first clinic visit at CCHMC in a regression analysis as well as the interaction between age at clinic visit and steroid duration, patients treated with deflazacort, on average, exhibited a significantly greater 4SC velocity compared with patients treated with prednisone (by 0.63 stairs/s) across all clinic visits at which this assessment was conducted (p < 0.001). On average in these adjusted analyses, across all clinic visits with assessments recorded, patients treated with deflazacort also had a greater 30-ft walk/run velocity (by 1.35 feet/s), a greater timed sit-to-stand velocity (by 0.13 1/s), a higher NSAA total score (by 4.7 points), a higher FVC %-predicted (by 9.2 percentage points), a higher % lean body mass (by 4.5 percentage points) and a lower % body fat (by 4.7 percentage points) compared with patients treated with prednisone (all p < 0.05). Patients treated with deflazacort also had a lower mean total body mass (by 6.7 kg) and were shorter on average (by 6.0 cm) compared with patients treated with prednisone (all p < 0.05). Similar results were observed when regression analyses for height and FVC %-predicted were additionally adjusted for the type of height assessment (e.g., standing, wingspan, segmental measurements). No significant differences between steroid types were observed across assessments for LVEF % or whole body BMD.
Discussion
This retrospective analysis of real-world data from a single, large DMD care center identified associations between the use of deflazacort and greater preservation of ambulatory and pulmonary function, and prolonged time to loss of ambulation and scoliosis, compared with the use of prednisone. Deflazacort was also associated with shorter stature, lower total bodyweight and greater % lean body mass. Loss of ambulation represents a clinically meaningful milestone in DMD progression [9, 11, 20] . The results of the present study align with prior evidence associating deflazacort with delayed loss of ambulation [9, [20] [21] [22] . For example, in a 2006 study conducted among 74 boys (ages 10-18 years) with DMD, patients treated with deflazacort (mean treatment duration 5.5 years) were able to rise from supine to standing, climb stairs and walk 10 meters without assistance for 3-5 years longer than those in a placebo group [22] . A 2015 study utilizing the Cooperative International Neuromuscular Research Group (CINRG) natural history database also associated deflazacort with delayed loss of ambulation; participants who received deflazacort treatment for ≥1 year had a median 3-year longer delay in loss of ambulation compared with those receiving prednisone (p < 0.001) [9] . Similarly, results of a 2018 study utilizing the CINRG database found that long-term treatment with deflazacort was associated with an increase in the median ages at the loss of ambulation by approximately 2 years compared with patients treated with prednisone [20] . Our finding of a near similar 2-year delay in the time to loss of ambulation with deflazacort compared with prednisone treatment in a single large care center, with homogenous care recommendations across patients, supports the prior finding, based on a global multi-center study, of a better motor outcome with deflazacort treatment compared with prednisone/prednisolone treatment.
Scoliosis is an important comorbidity of DMD that is closely associated with muscle weakness and loss of ambulation [23] [24] [25] . The consequences of scoliosis are significant, and complications associated with surgery to correct spinal deformities can further exacerbate the disease burden in DMD [23] . The lower risk of scoliosis observed among patients receiving deflazacort compared with prednisone in the current study is clinically meaningful, and concordant with the greater preservation of ambulatory function observed among the deflazacort-treated patients.
While there were only a small number of patients switching from prednisone to deflazacort in the present study, this group exhibited hazards of loss of ambulation and scoliosis that were numerically intermediate relative to patients who consistently received prednisone (highest risk) and those who initiated deflazacort (lowest risk).
In addition to studying ages at clinical events, our study assessed differences between deflazacort-and prednisonetreated patients across all clinic visits. Differences in ambulatory function across visits reached magnitudes deemed clinically meaningful in prior research [26] [27] [28] . For example, a previous study reported that a difference of 2-4 points in the NSAA total score and a difference of 0.3-0.6 stairs/s in 4SC velocity represent clinically meaningful differences [28] . Across clinic visits, the present study found numerically higher performance on NSAA (by 4.6 points) and 4SC velocity (by 0.59 stairs/s) associated with deflazacort compared with prednisone use, after accounting for the patient's age and duration of steroid treatment at the clinic visit.
The lower weight and shorter height among patients treated with deflazacort versus prednisone in the present study replicate well-known associations for these treatments [14, 29, 30] . Underlying these changes in overall body size, deflazacort was associated with a more favorable body composition compared with prednisone in the present study, with higher % lean body mass and lower % body fat. As lean mass largely reflects muscle mass [31] , the higher levels of % lean body mass observed among patients using deflazacort versus prednisone align with the observed differences in ambulatory function between the two treatment groups.
This study found no evidence of a difference in whole body BMD between deflazacort-and prednisone-treated patients. This was surprising given that a previous study has associated daily deflazacort with an annualized fracture risk of 1367 per 10,000 person years, an almost twofold higher risk compared with daily prednisone [32] . Fracture data were not available for the current study, and further investigation of this outcome is needed. Other adverse effects of steroids that were not available in the present database but warrant further study include Cushingoid appearance, insulin resistance and behavioral changes.
Declines in respiratory function due to progressive muscle weakening are a significant contributor to the morbidity and mortality in DMD [33] . Patients receiving deflazacort in the present study had, on average, better pulmonary function with higher FVC %-predicted compared with patients receiving prednisone. The higher %predicted values for deflazacort-treated patients versus prednisone/prednisolone-treated patients may be related to the shorter stature of deflazacort-treated patients since height is the denominator for calculating FVC %-predicted FVC. Greater preservation of pulmonary function with deflazacort was also observed in the aforementioned 2018 study utilizing the CINRG database, which estimated a delay in median age at FVC <1L by approximately 2 years compared with treatment with prednisone [20] .
Cardiac disease is the primary cause of mortality in over 20% of patients with DMD due to the dystrophin gene defect causing an absence of the muscle cytoskeletal protein dystrophin and leading to cardiac muscle disease [34] [35] [36] . This study found no evidence of a difference in LVEF % between patients treated with deflazacort or prednisone. Patients in both the deflazacort and prednisone groups had an average LVEF % of over 55% (59 and 58%, respectively), indicating that LVEF % was preserved during the majority of follow-up.
Limitations
The principal limitation of this study is that steroid use was not randomized as in a clinical trial. Therefore, differences in outcomes between steroid groups could be confounded by factors that differ between these groups. Some of these factors could be accounted for in our analyses via regression adjustment. For example, the younger average age at steroid initiation for deflazacort-treated patients could impact outcomes, but was accounted for by adjusting for age at steroid initiation. It could also be hypothesized that differences in care received prior to CCHMC, including potential differences in steroid dosing or supportive care, could have impacted outcomes. Indeed, a higher proportion of patients initiating prednisone did so prior to CCHMC compared with those initiating deflazacort. For this reason, our analyses adjusted for whether or not steroids were initiated prior to the first clinic visit at CCHMC, among other factors. However, despite these adjustments for observed differences between groups, it is possible that unobserved differences are present. In particular, it was not possible to identify the extent to which potential differences in socioeconomic status (SES) may have affected the results. Cost has been a factor for most families at CCHMC who opt for prednisone instead of out-of-pocket, imported deflazacort. Prednisone is also cheaper in other countries. Generally, families at CCHMC with higher SES tend to have better adherence to care future science group www.futuremedicine.com plans. For example, care plans may include recommendations for self-or family-administered physiotherapy such as stretching, night brace usage and nutritional/weight management; adherence to these recommendations could be impacted by SES through differences in self-efficacy, social support, or anxiety/depression [37, 38] . The impact of different dosing regimens is a plausible contributor to the differences in outcomes observed in the present study between patients receiving prednisone and deflazacort. In particular, the impact of excessive weight gain with prednisone/prednisolone [14] could have resulted in lower tolerated doses of prednisone/prednisolone as in the CINRG cohort (cumulative dose of daily prednisone patients was 1729 mg or equivalent deflazacort dose of 2075 mg vs cumulative dose of 2922 mg) [20] . In this way, differences in functional outcomes and scoliosis risk could be explained by better tolerability of deflazacort to enable more optimal dosing of recommended 0.9 mg/kg/day as opposed to a lower dose of prednisone due to its side effect of excessive weight gain. Indeed, a randomized trial of fixed daily doses of prednisone (0.75 mg/kg/day) and deflazacort (0.9 mg/kg/day) identified no significant differences in motor function, but substantially greater weight gain with prednisone [14] . While sensitivity analyses separating out daily and other regimens of prednisone identified results consistent with those of the main analyses, our study is limited by the lack of data on cumulative or time-varying doses of deflazacort and prednisone. It was not possible to compare dose-adjusted outcomes. Rather, the outcomes observed in the present study represent those associated with real-world, individualized dosing for each steroid type at CCHMC. Beyond differences in dosing, other potential differences between deflazacort and prednisone, including greater reduction of interferon gamma levels [39] and potential immunomodulatory effects [39] [40] [41] [42] , or lower protein binding and nonaffinity for transcortin and potential impacts on bioavailability in muscle fibers [43] [44] [45] [46] , could be speculated to impact functional outcomes, but were not investigated in the present study.
As a study of real-world data captured in clinical practice, there are also limitations stemming from the data collection process. In particular, ambulatory test results were not available from patients who were unable or unwilling to complete the assessments. Thus, the cross-sectional analyses of ambulatory function represent differences among patients who completed those tests.
Conclusion
This study of real-world data adds to the evidence from other observational studies associating the use of deflazacort with greater preservation of motor and pulmonary function relative to the use of prednisone, and further indicates concurrent preservation of lean body mass and delay of scoliosis.
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